Modulation of the Lung Inflammatory Response to Serotype 8 Pneumococcal Infection by a Human Immunoglobulin M Monoclonal Antibody to Serotype 8 Capsular Polysaccharide
Open Access
- 1 August 2005
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 73 (8) , 4530-4538
- https://doi.org/10.1128/iai.73.8.4530-4538.2005
Abstract
The human monoclonal antibody to serotype 8 pneumococcal capsular polysaccharide D11 [immunoglobulin M(κ)] protects wild-type and complement component 4 knockout (C4 KO) mice against lethal intratracheal challenge with serotype 8 pneumococcus, but it does not promote polymorphonuclear leukocyte (PMN)-mediated pneumococcal killing in vitro. In this study, we investigated the effect of D11 on the blood and lung bacterial burdens and the serum and lung expression of inflammatory chemokines and cytokines in an intratracheal challenge model with serotype 8 pneumococcus in C4 KO mice. Pneumococcus was not detected in the blood of D11-treated mice, whereas control mice had high-grade bacteremia with >107 CFU. Control mice had a >5-log increase in lung CFU and D11-treated mice manifested a nearly 3-log increase in lung CFU compared to the original inoculum 24 h after infection. Serum and lung levels of soluble macrophage inflammatory protein 2 (MIP-2) and interleulin-6 (IL-6) as measured by an enzyme-linked immunosorbent assay were lower in D11-treated mice than in control mice 24 h after infection. Real-time PCR was performed to examine lung mRNA chemokine and cytokine expression. The results showed that D11-treated mice had significantly less gamma interferon, MIP-2, IL-12, monocyte chemoattractant protein 1/JE, and tumor necrosis factor alpha expression than control mice 24 h after infection. Histopathology and immunohistochemical staining of lung tissues revealed that D11-treated mice had less inflammation, fewer PMNs, and less myeloperoxidase staining than control mice 24 h after infection. These findings suggest that the efficacy of certain serotype-specific antibodies against pneumococcal pneumonia could be associated with modulation of the lung inflammatory response and a reduction in host damage.Keywords
This publication has 85 references indexed in Scilit:
- Activation of Neutrophils and Inhibition of the Proinflammatory Cytokine Response by Endogenous Granulocyte Colony‐Stimulating Factor in Murine Pneumococcal PneumoniaThe Journal of Infectious Diseases, 2004
- Improved Host Defense against Pneumococcal Pneumonia in Platelet‐Activating Factor Receptor–Deficient MiceThe Journal of Infectious Diseases, 2004
- Vaccines for preventing pneumococcal infection in adultsPublished by Wiley ,2003
- Streptococcus pneumoniae–Associated Human Macrophage Apoptosis after Bacterial Internalization via Complement and Fcγ Receptors Correlates with Intracellular Bacterial LoadThe Journal of Infectious Diseases, 2003
- Administration of Either Anti-Intercellular Adhesion Molecule-1 or a Nonspecific Control Antibody Improves Recovery after Traumatic Brain Injury in the RatJournal of Neurotrauma, 2002
- Structure-Function Relationships for Human Antibodies to Pneumococcal Capsular Polysaccharide from Transgenic Mice with Human Immunoglobulin LociInfection and Immunity, 2002
- Modulation of Cytokines and Chemokines, Limited Pulmonary Vascular Bed Permeability, and Prevention of Septicemia and Death with Ceftriaxone and Interleukin?10 in Pneumococcal PneumoniaThe Journal of Infectious Diseases, 2000
- Elderly Humans Show Prolonged In Vivo Inflammatory Activity during Pneumococcal InfectionsThe Journal of Infectious Diseases, 1999
- Induction of Phagocyte‐Stimulating and Th1‐Promoting Cytokines by In Vitro Stimulation of Human Peripheral Blood Mononuclear Cells with Streptococcus pneumoniaeScandinavian Journal of Immunology, 1999
- Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia.Journal of Clinical Investigation, 1995